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Hypothermic Oxygenated Perfusion (HOPE) Downregulates the
Immune Response in a Rat Model of Liver Transplantation
Andrea Schlegel, MD,∗ Philipp Kron, MD,∗ Rolf Graf, PhD,∗ Pierre-Alain Clavien, MD, PhD,∗†
and Philipp Dutkowski, MD∗
Objective: To evaluate the impact of a novel oxygenated perfusion approach
on rejection after orthotopic liver transplantation (OLT).
Background: Hypothermic oxygenated perfusion (HOPE) was designed to
prevent graft failure after OLT. One of the mechanisms is downregulation
of Kupffer cells (in situ macrophages). We, therefore, designed experiments
to test the effects of HOPE on the immune response in an allogeneic rodent
model of nonarterialized OLT.
Methods: Livers from Lewis rats were transplanted into Brown Norway rats
to induce liver rejection in untreated recipients within 4 weeks. Next, Brown
Norway recipients were treated with tacrolimus (1 mg/kg), whereas in a third
group, liver grafts from Lewis rats underwent HOPE or deoxygenated ma-
chine perfusion for 1 hour before implantation, but recipients received no
immunosuppression. In a last step, low-dose tacrolimus treatment (0.3 mg/kg)
was assessed with and without HOPE.
Results: Allogeneic OLT without immunosuppression led to death within
3 weeks after nonarterialized OLT due to severe acute rejection. Full-dose
tacrolimus prevented rejection, whereas low-dose tacrolimus led to graft fi-
brosis within 4 weeks. HOPE treatment without immunosuppression also
protected from lethal rejection. The combination of low-dose tacrolimus and
1-hour HOPE resulted in 100% survival within 4 weeks without any signs of
rejection.
Conclusions: We demonstrate that allograft treatment by HOPE not only
protects against preservation injury but also impressively downregulates the
immune system, blunting the alloimmune response. Therefore, HOPE may
offer many beneficial effects, not only to rescue marginal grafts but also by
preventing rejection and the need for immunosuppression.
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(Ann Surg 2014;260:931–938)
O rthotopic liver transplantation (OLT) offers a unique chanceto treat patients with end-stage liver disease. The persistent
need for lifelong immunosuppressive treatment, however, is a major
shortcoming in terms of several serious side effects including infec-
tious complications,1 long-term nephrotoxicity,2 and primary tumor
recurrence3 or secondary tumor growth.4 For these reasons, novel
strategies decreasing the need of immunosuppressive treatment after
transplantation seem highly attractive.
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Recently, we have presented the worldwide first results of a
newly developed machine liver perfusion approach for human liver
grafts, donated after cardiac death.5 The perfusion technique con-
sisted of a short-term hypothermic oxygenated perfusion (HOPE) af-
ter conventional organ procurement and cold storage and was shown
to protect effectively from ischemia-reperfusion (I/R) injury despite
long donor warm ischemia times.6–8 We have also reported, in several
experimental studies, that such effects of HOPE depend on oxygena-
tion of the perfusate6 with decreased downstream activation of numer-
ous inflammatory pathways.6,7 On the basis of these findings, the aim
of the current study was to analyze effects of HOPE treatment on the
immune response in a model of acute rejection, using incompatible
rat strains for OLT.9 We compared allogeneic liver transplants with
and without immunosuppressive or HOPE treatment. In addition, to
provide mechanistic insights, we added perfusion experiments with
a deoxygenated perfusate. We focus on T-cell response and survival
within 30 days after liver transplantation.
METHODS
Animals
Male Lewis and BrownNorway rats (250–320 g) were used for
all experiments. Animals received standard laboratory diet and water
according to the Swiss Animal Health Care law, and experiments were
approved by the animal ethics committee. Anesthesia during liver
procurement and transplantation was maintained with isoflurane.
Study Design
Transplantation of livers from Lewis rats into Brown Norway
recipients has previously been shown to induce rejection.9–12 Using
this strain combination, we compared in an allogeneic liver transplant
model the impact of HOPE against standard immunosuppression. We
selected the following experimental groups (see Supplemental Digital
Content Fig. 1, available at http://links.lww.com/SLA/A649):
I. Syngeneic control: Livers from Brown Norway rats were pro-
cured and implanted into Brown Norway recipients (Syngeneic
control).
II. Untreated group: Livers from Lewis rats were procured and
transplanted into Brown Norway recipients without any addi-
tional treatment (Untreated).
III. Full immunosuppression: Livers from Lewis rats were procured
and transplanted into Brown Norway recipients, which received
full immunosuppressive treatment with tacrolimus intramuscu-
larly (1 mg/kg of bodyweight/d), starting before recipient hepa-
tectomy (TAC).
IV. Low-dose immunosuppression:Livers fromLewis rats were pro-
cured and transplanted into Brown Norway recipients, which re-
ceived a reduced immunosuppressive treatment with tacrolimus
intramuscularly (0.3 mg/kg of bodyweight/d), starting before
recipient hepatectomy (low TAC).
V. HOPE group: Livers from Lewis rats were procured, machine
perfused with an oxygenated perfusate (HOPE) for 1 hour, and
transplanted without any additional recipient treatment (HOPE).
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Annals of Surgery  Volume 260, Number 5, November 2014 www.annalsofsurgery.com | 931
Schlegel et al Annals of Surgery  Volume 260, Number 5, November 2014
VI. HNPE group: Livers from Lewis rats were procured, machine
perfused with a nitrogenated perfusate (HNPE) for 1 hour,
and transplanted without any additional recipient treatment
(HNPE).
VII. HOPE + low-dose immunosuppression: Livers from Lewis rats
were procured, machine perfused with an oxygenated perfusate
(HOPE) for 1 hour, and transplanted into Brown Norway recip-
ients, which received a reduced immunosuppressive treatment
with tacrolimus intramuscularly (0.3 mg/kg of bodyweight/d),
starting before recipient hepatectomy (HOPE + low TAC).
Endpoints
We analyzed hepatocyte necrosis, Kupffer cell activation, en-
dothelial cell activation, and T-cell activation by specific staining
procedures 24 hours after OLT in each group. In additional ex-
periments, we documented plasma alanine aminotransferase (AST),
bilirubin, high mobility group box-1 protein (HMGB-1), 8-hydroxy-
2-deoxy guanosine (8-OHdG), interleukin (IL)-2, IL-10, and inter-
feron gamma (IFN-γ ) during 14 days after OLT. The T-cell response
after 2 weeks was investigated by fluorescence-activated cell-sorting
(FACS) analysis in blood samples. Additional staining procedures
were performed 2 and 4 weeks after transplantation to confirm tissue
remodeling into liver fibrosis and rejection. Follow-up for survival
after OLT was 4 weeks.
Liver Procurement and OLT
Donor livers were freed from ligaments and flushed with
6 mL of heparinized (1 U/mL) saline at room temperature via the
portal vein. Livers were excised (weight 9.7 ± 1.5 g) and placed
in precooled UW solution (4◦C). Afterward, non–machine-perfused
livers received cuffs for the portal vein and the infrahepatic vena
cava whereas livers allocated to the perfusion groups received first a
stent for the portal vein and later cuffs after machine perfusion. Cold
storage was approximately 30 minutes in all experimental groups.
Nonarterialized liver transplantation was performed after procure-
ment ormachine perfusion according to the technique byKamada and
Calne.13
HOPE and HNPE
Livers from Lewis rats to be cold perfused were connected to
the precooled perfusion device and perfused for 1 hour through the
portal vein with a constant perfusion pressure of 3 mm Hg or less.14
We used 50 mL of recirculating modified starch-free UW solution
as perfusate.7,8 Perfusion box and perfusate were maintained at 4◦C
by an open bath thermostat (Huber, Germany). In all HOPE exper-
iments, the cold perfusate was actively oxygenated (pO2 >60 kPa)
(HOPE group). In theHNPE group, oxygen was replaced by nitrogen
(pO2 <2 kPa) (HNPE group).
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FIGURE 1. Liver injury 24 hours after OLT: allogeneic liver transplantation without immunosuppression induced hepatocyte injury
and Kupffer and endothelial cell activation during the first day after reperfusion (A–C). HOPE treatment significantly protected
hepatocytes from reperfusion injury (A). Macrophages and endothelial cells after HOPE also appeared less activated (B, C).
Machine perfusion with a deoxygenated perfusate (HNPE) induced the same degree of injury after OLT as untreated allogeneic
controls (A–C). Treatment with tacrolimus showed less effect on Kupffer cell activation compared with HOPE (B). One day after
OLT, CD3-positive T cells in livers were rarely detectable in all experimental groups (D). H&E indicates hematoxylin-eosin; TAC,
tacrolimus; vWF, von Willebrand factor.
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Assays
Hepatocyte injury after transplantation was measured by AST
release and total bilirubin (serummultiple biochemical analyzer DRI-
CHEM4000i; FUJIFILM, Japan). Oxidative damage of DNA by
oxygen free radicals was detected using an 8-OHdG enzyme-linked-
immunosorbent assay (Abnova, KA0444). Nuclear subcellular injury
wasmeasured by release of HMGB-1 using a specific enzyme-linked-
immunosorbent assay (IBL International GmbH, ST51011). In addi-
tion, several markers indicating graft rejection were analyzed in the
rat plasma after transplantation, that is, IL-2 (IBL, 87728012), IL-10
(R&D, R1000), and IFN-γ (R&D, RIF00).
FACS Analysis
After blood retrieval, 1.5 mL of heparinized full rat blood
was used for this analysis. After white blood cell isolation us-
ing Ficoll and DMEM+P/S buffer, cells were incubated with var-
ious combinations of mAbs (anti-Rat CD3, PerCP-eFluor710 sin-
gle staining, anti-rat CD4-PE combined with anti-rat CD25-FITC,
anti-rat CD8-FITC combined with anti-rat CD28-PE), washed twice
with FACS buffer, and fixed with 1% paraformaldehyde. Three-
color immunofluorescence staining was analyzed using a FACS
Calibur instrument (FACS diva, version 6.1.2). The lymphocytes
were gated using forward and side scatter to exclude debris and
dead cells. Afterward, 50,000 events were acquired in each assay for
analysis.
Histological Examinations
The following staining procedures were performed after
transplantation: hematoxylin-eosin staining for necrosis, Sirius red
for fibrosis, CD68 staining for Kupffer cell activation, CD80/86
staining for antigen presenting cells, von Willebrand factor staining
for endothelial activation, and CD3 staining for T lymphocytes.
Quantification of CD68-positive cells, CD80-positive cells, von
Willebrand factor–positive endothelial cells, and CD3-positive
lymphocytes in liver tissue was performed in 8 random fields of 2
slides per animal, resulting in 160 quantified fields per experimental
group. Acute rejection was assessed on hematoxylin-eosin staining
and based on portal inflammation, bile duct inflammation, and
endothelial inflammation,15 and signs of chronic rejection based on
portal inflammation, bile duct damage, obstructive arteriopathy, and
graft fibrosis.16
Statistics
Data are presented as means ± standard deviation. Statisti-
cal analysis was performed using the nonparametric Mann-Whitney-
Wilcoxon U test (GraphPadPrism, version 4.0; San Diego, CA).
RESULTS
Acute Rejection Without and With
Immunosuppressive Therapy in an Allogeneic Rat
Liver Transplant Model
In a first step, we documented the degree of liver graft injury in
an allogeneic rat liver transplant model (donor livers from Lewis rats
into Brown Norway recipients)9,10 in contrast to syngeneic transplant
controls. Recipientswithout immunosuppressive treatment developed
severe graft injury within 24 hours after OLT, confirmed by nuclear
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FIGURE 2. Liver injury during 2 weeks after allogeneic OLT: Recipients without immunosuppression developed elevated levels
of liver enzymes (A), bilirubin (B), IL-2, IL-10 (E, F), and IFN-γ (G). Nuclear injury and oxidative stress markers (ie, HMGB-1,
and 8-OHdG) increased in untreated allogeneic grafts and also in livers perfused with deoxygenated perfusate (HNPE group)
(C, D). Immunosuppression (TAC) had no effect on initial DAMP molecule and reactive oxygen species release but protected from
the release of rejection markers (E–G). HOPE treatment led, first, to significantly decreased reperfusion injury, as shown by less
amounts of oxidized DNA (C) and HMGB-1 (D), and second, induced less IL-2, IL-10, and IFN-γ release (E–G) during 2 weeks
after OLT. Machine perfusion without oxygen abrogated the effect of HOPE (A–G). TAC indicates tacrolimus.
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injury (8-OHdG and HMGB-1 release), AST release, and Kupffer
and endothelial cell activation (Figs. 1, 2). Subsequently, in these
animals, we observed acute rejection during the first 2 weeks after
transplantation, as documented by massive T-cell infiltration (Fig. 3),
along with persistent high blood levels of AST, bilirubin, IL-2, IL-10,
and IFN-γ (Fig. 2). In addition, Sirius red staining in liver samples
after 2 weeks revealed severe graft fibrosis (Fig. 4). Such degree
of injury was lethal in all untreated recipients during 18 days after
allogeneic OLT (Fig. 3) despite choosing experimental conditions
with minimal exposure of liver grafts to cold and warm ischemia (see
Supplementary Fig. 1, available at http://links.lww.com/SLA/A649).
In a next step, we treated recipients before graft implantation
with tacrolimus (1 mg/kg of body weight/d),9 resulting in a trough
level of 8 to 10 ng/l, according to earlier studies.9 Such degree of
immunosuppression protected significantly from endothelial cell ac-
tivation 24 hours after OLT (Fig. 1). In addition, within the following
2 and 4 weeks, infiltration of T cells in liver grafts remained low
(Fig. 3). These findings were paralleled by the decreased amount of
circulating activated T cells (Fig. 3) and low cytokine levels in blood
(Fig. 2). Recipient survival increased to 80% within 4 weeks (6/8)
(Fig. 3).
Finally, we reduced immunosuppressive therapy to one third
of the daily dose (0.3 mg/kg of body weight/d) resulting in a trough
level of 3 to 4 ng/l. With this low-dose tacrolimus therapy, recipients
survived (6/8) but developed liver fibrosis within 4 weeks after OLT
(Fig. 5).
In summary, allogeneic nonarterialized rat liver transplantation
without immunosuppression led to severe acute rejection, liver fibro-
sis, and animal death within 3 weeks. Lethal rejection and fibrosis
within 4 weeks were prevented with adequate tacrolimus treatment
of recipients, whereas low-dose tacrolimus induced graft fibrosis and
chronic graft injury.
Liver Graft Protection by Short-term Application
of HOPE Without Immunosuppressive Treatment
To investigate the effects of HOPE on the immune response in
the same allogeneic transplant model, we perfused donor livers from
Lewis rats for 1 hour and implanted perfused liver grafts in Brown
Norway recipients, without any immunosuppressive treatment. As
expected from previous studies,6,8 HOPE reduced reperfusion injury
within the first 24 hours after OLT, confirmed by minimal 8-OHdG,
HMGB-1, and AST release and decreased activation of Kupffer and
endothelial cells (Figs 1, 2). Furthermore, HOPE treatment prevented
infiltration of CD3-positive T cells in liver grafts (Fig. 3) consistent
with low levels of IFN-γ , IL-2, and IL-10 (Fig. 2). Two weeks af-
ter HOPE treatment and OLT, quantification of circulating activated
CD3-positive T cells remained low (Fig. 3) and graft fibrosis and
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FIGURE 3. T-cell activation and survival 2 to 4 weeks after OLT: The number of circulating T cells in blood was quantified by FACS
analysis (A). CD28- and CD25-positive T cells were less observed in recipients of HOPE-treated livers and also in animals with full
immunosuppression (FACS analysis) (A). The number of infiltrating T cells in liver grafts was significantly reduced in HOPE- and
TAC-treated animals (B). HOPE and TAC treatment increased recipient survival, whereas untreated controls died within 2 weeks
after OLT (C). TAC indicates tacrolimus.
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FIGURE 4. HOPE treatment led to significant reduction of CD80/86-positive cells and protected from high-grade fibrosis compared
with untreated recipients and machine perfusion without oxygen (HNPE) (A–C). However, HOPE without any immunosuppression
induced mild fibrosis (C) not seen under full immunosuppression (TAC) (A–C). H&E indicates hematoxylin-eosin; HPF, high power
field; TAC, tacrolimus.
survival appeared significantly improved by HOPE compared with
untreated liver grafts within 4 weeks after OLT (Figs. 3, 4). However,
graft histology after 4 weeks disclosed increased signs of chronic in-
jury comparable with those seen with low-dose tacrolimus treatment
(Fig. 5).
On the basis of these experiments, we conclude that HOPE
treatment of grafts protects from activation of the early immune re-
sponse in recipients and rescued from lethal injury in an allogeneic
nonarterialized liver transplant model. Yet, HOPE alone, without any
further immunosuppression, failed to prevent chronic graft injury.
Immune Response After Machine Perfusion
Without Oxygen
Previous results have shown that protection against I/R injury
depended on the presence of oxygen in the machine perfusate during
HOPE.6 Here, we analyzed whether early immune response of the
recipient was also mediated through oxygenation effects. For this
purpose, we perfused liver grafts from Lewis rats with a nitrogenated
perfusate (HNPE) at 4◦C (pO2 level <2 kPa). Livers perfused with
this technique demonstrated significant higher degrees of reperfusion
injury after OLT in BrownNorway recipients, confirmed by release of
damage associatedmolecular pattern (DAMP)molecules (HMBG-1),
AST, and cytokines (IL-10, IL-2, IFN-γ ) and Kupffer and endothelial
cell activation (Figs. 1, 2). Furthermore, machine perfusion in the
absence of oxygen abrogated downstream the protective effect of
HOPE on activation of T cells (Fig. 3) and led to acute liver graft
rejection, fibrosis (Fig. 4), and death of all recipients within 4 weeks
after OLT (Fig. 3), similarly as in untreated recipients. On the basis
of this, the effect on the direct immune response by HOPE seems to
be mediated by perfusate oxygen and points therefore to an initial
mitochondrial protection during machine perfusion, with subsequent
decreased release of reactive oxygen species and DAMP molecules.
Liver Graft Protection With Low-Dose Tacrolimus
in Combination With HOPE
In a last experimental step, we combined graft treatment by
HOPE and low-dose immunosuppressive therapy. With this strategy,
all recipients survived for 4weekswithout signs of rejection or fibrosis
in contrast to recipients under low-dose tacrolimus without HOPE
(Fig. 5).We conclude that the addition of HOPE before OLT allows to
reduce immunosuppressive therapywithout increased risk of rejection
in an allogeneic rodent transplant model.
DISCUSSION
This study showed that liver allograft treatment by an easy
applicable machine perfusion approach before OLT not only is
effective against reperfusion injury but also prevents activation of
the immune response pathways. This was evident, first, by decreased
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FIGURE 5. Immune response 4 weeks after OLT: Reduction of tacrolimus to levels between 4 and 5 ng/l (C) induced liver fibrosis
and T-cell infiltration within 4 weeks (D). Adding HOPE before OLT prevented significantly liver injury, fibrosis, and T-cell infiltration
within 4 weeks despite low-dose TAC treatment (A–F). TAC indicates tacrolimus.
Kupffer and endothelial cells activation after HOPE treatment and
OLT, followed by decreased T-cell infiltration in liver grafts, and also
by a decreased amount of circulating and activated T cells in blood.
Of note, the initial effect of HOPE treatment on the direct immune
response pathway appeared comparable with the immunosuppression
conferred by tacrolimus. Furthermore, whereas a significant reduc-
tion of immunosuppressive treatment provoked graft fibrosis within
4 weeks, the addition of HOPE before OLT protected from signs of
chronic graft injury.
Next, we demonstrated that the effect of HOPE against an
immune response depends on oxygenation of the perfusate along
with strong impact against reperfusion injury.7 Consistently, HOPE
treatment prevented from lethal graft rejection in an allogeneic trans-
plant model whereas hypothermic perfusion using a deoxygenated
perfusate failed to protect from acute rejection. It seems therefore
unlikely that washout effects of immunocompetent cells during ma-
chine perfusion contribute to the decreased immune response ob-
served in HOPE-treated livers. This important finding is consistent
with previous studies, which have underlined a key role of oxy-
gen and mitochondrial function during HOPE.6,7,17 In parallel, end-
ischemic oxygenated cold perfusion of porcine kidneys has recently
been shown to reduce the innate immune response, as evaluated
by HMGB-1 release and gene expression of toll like receptor-4
(TRL-4).18
Liver graft injury arises during the transplantation process from
several sources, that is, as a result of donor brain or cardiac death,
from cold storage, and from warm ischemia and reperfusion in the
recipient. It is believed that hypoxia during procurement, preserva-
tion, and implantation triggers the release of reactive oxygen species
in different compartments and the release of DAMP molecules, char-
acterized by extracellular matrix fragments, nucleic acids, histones,
and HMGB-1.19,20 DAMP molecules bind to Kupffer cells, dendritic
cells, leukocytes, and endothelial cells by numerous toll like recep-
tors (TRL-2, TLR-3, TLR-4. TLR-7, TLR-9) and receptor for ad-
vanced glycation end products (RAGE).20–24 Recognition of DAMP
molecules through these receptors activate both donor- and recipient-
derived dendritic cells, besides activation by other factors such as
complement and lymphocytes.14,25–27 It has recently been suggested,
therefore, that prevention of an initial oxidative stress and DAMP
molecule release in donors and recipients could be a key option for
subsequent modulation of immune and inflammatory responses.28
However, available free radical scavengers or other pharmacological
approaches have failed in clinical practice, due to their low activity
at the time and site of graft injury.29 In contrast, hypothermic oxy-
genated machine perfusion before implantation, initially developed
to rescue marginal liver grafts,5 offers a unique chance to impact on
the main source of intracellular oxidative stress due to changes in the
mitochondrial redox state6 before implantation. On the basis of this,
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such machine perfusion technique potentially impacts on donor im-
munogenic cells before any exposure to recipient cells. Accordingly,
we show here, for the first time, in a rodent liver transplant model that
1-hour perfusion with a cold oxygenated perfusate before OLT was
highly efficient in preventing lethal rejection, suggesting a direct link
between early reperfusion injury after organ transplantation and the
initiation of the immune response.30
Machine perfusion strategies may, therefore, not only improve
initial organ function by decreasing reperfusion injury but also reduce
immune response by less activation of tissue-resident dendritic cells.
We opted in this study for a nonarterialized allogeneic rat OLT
model for 2 reasons. First, previous studies in rats have shown con-
sistently that a nonarterialized rat OLT model was highly suitable for
rejection studies within 4weeks after OLT.9,11,31,32 Second, additional
hepatic artery reconstruction prolonged survival but finally failed to
prevent chronic rejection and graft dysfunction.31,32
Translation of our results to the human situation may require
longer follow-up and experiments in large animals. Further investi-
gations should also include nonstandard liver grafts, that is, extended
criteria grafts or liver grafts donated after cardiac death, as we choose
in this study an experimental model without previous exposure to
warm or cold ischemia.
CONCLUSIONS
HOPE-treated liver grafts may tolerate a significant lower im-
munosuppressive treatment. If confirmed in the clinic, the use of
HOPE may open the door for regimens with significant low or de-
layed calcineurin inhibitors without a risk of graft rejection, but less
toxic effects in high MELD recipients or donated after cardiac death
liver transplants.33,34 In addition, underlying recipient diseases that
require minimal immunosuppressive treatment, that is, recurrent hep-
atitis C,35 or advanced hepatic tumors36 could benefit from this new
strategy.
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DISCUSSANTS
J. Lerut (Brussels, Belgium):
Thank you very much for your elegant presentation and
nice article on the potential immunologic benefit of hypothermic
oxygenated machine perfusion in liver transplantation. This work is a
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good example of a well-conducted experimental work in the field of
small animal liver transplantation, going 7 steps further from a syn-
geneic control group to a HOPE-tacrolimus group. Scientific work
on the minimization of immunosuppression is especially welcomed
in an era of extended criteria donors and a shift of interest within the
transplant community to long-term survival.
In the “low-dose tacrolimus and HOPE” group, acute rejection
and fibrosis were markers of chronic rejection and were eliminated in
a model on nonarterialized liver transplantation.
In summary, all your findings come down to a well-known
relationship between the degree of the I/R injury and the incidence of
immunologic events, such as rejection. This linkwas a substantial part
of the research, conducted by Prof Tilney, from Boston. As HOPE,
through the impact on the mitochondrial function, downregulates the
I/R injury and the innate immune response, it was logical to also
search for a possible downregulation of adaptive immunologic events
in your experimental setting.
You concluded that the combination of HOPE and low-dose
tacrolimus eliminated rejection and fibrosis. It must, however, be
said that it is nowadays possible, in clinical practice, to obtain ex-
cellent (immunologic) outcome under minimal immunosuppression.
It could also be possible that the unfavorable immunologic events
you documented in the non-tacrolimus groups were reinforced by the
nonarterialized model of liver transplantation. So, a question arises,
pertaining to the real impact of HOPE on your observations. There-
fore, I have 2 questions in relation to this.
The first relates to the use of a nonarterialized rat model of liver
transplantation. Indeed, the Tokyo Shimizu group showed that T-cell
infiltration and immunoglobulin deposition, in sync with antibody-
mediated rejection, are much more pronounced in the nonarterialized
liver transplantation model. So, in the arterialized model, the effect of
HOPE could be less pronounced. Do you intend to add an arterialized
model of liver transplantation to your already extensive number of
models?
My second question, which is of great significance, relates to
a more in-depth explanation of the underlying immunologic mecha-
nisms of your findings. HOPE alone postpones the rejection and trans-
forms this event into a chronic add-on; even adding small doses of
tacrolimus to HOPEmay inhibit the B-cell response. It is, thus, neces-
sary to observe the production of anti-HLA antibodies to confirm the
immunologic protective effect of HOPE. Indeed, accelerated fibrosis
may be linked to antibody production, with the following activa-
tion of the complement cascade and innate immunity (macrophages,
monocytes, etc). Did you have the opportunity to observe the im-
mune B response in your research, and if so, what was the result?
This information is absolutely imperative, before one can claim that
HOPE alone is able to downregulate the immune response of the liver
recipient.
Response From P. Dutkowski (Zurich, Switzerland):
Thank you very much Prof Lerut for these kind comments and
good questions. I would like to return to your first point, regarding an
arterialized transplant model.We chose, on purpose, a nonarterialized
rat liver transplantation, because, as you also mentioned, rejection is
known to occur to a higher degree without arterialization. To test the
maximum effect of HOPE, we, therefore, opted for a nonarterialized
transplantation in this study and showed a strong effect.
The second question focuses on the effect of HOPE on the in-
direct immune pathway. At this stage, we cannot say something about
the effect of HOPE on B-cell response and downstream mediators.
This issue should be addressed by further studies.
DISCUSSANTS
M. Krawczyk (Warsaw, Poland):
Professor Dutkowski, I appreciated your article very much.
Your excellent study is very important for the future of liver trans-
plantation, as the shortage of donors is a problem for most transplant
centers.
Here are my 2 questions:
First, you say that for these types of liver recipients, you would
recommend the use of hypothermic oxygenated machine perfusion.
Do you mean that it would be possible to use it for urgent recipients?
If we have an urgent recipient, at the time of transplantation, this is
really crucial. We know that the use of HOPE is time-consuming. Do
you share my opinion that a benefit of HOPE has a higher effect than
the time of the transplantation?
Second, I would like to ask you, whether HOPE could be
used for blood group incompatibility in liver transplantation. From
personal experience, I know that the number of acute rejections, in
this group of patients, is higher than in blood group compatibilities
in liver transplantation.
Once again, congratulations on your excellent presentation. I
will be pleased to hear the answers to my 2 questions.
Response From P. Dutkowski (Zurich, Switzerland):
Thank you very much, Prof Krawczyk, for these good ques-
tions. In fact, applying HOPE is possible without losing time, as the
oxygenated perfusion is done during recipient hepatectomy, which
makes this method very simple.
The question, regarding blood group incompatibility, is dif-
ficult to address at the moment, because our study is the first to
suggest an effect on the immune response, by a simple ex vivo graft
treatment, before transplantation. Whether this technique is strong
enough to avoid rejection in incompatible livers requires further
investigation.
DISCUSSANTS
R. Adam (Villejuif, France):
I congratulate you and your team for acquiring further evidence
for the advantage of machine perfusion on the liver.
I have one, simple question: Do you think that theminimization
of ischemic injury to the liver directly influenced this type of effect
on the minimization of allograph rejection, or is this a completely
independent factor?
Second, to demonstrate that oxygen is key in the minimiza-
tion of the graph rejection, have you done or do you plan to do an
experiment with HOPE, without oxygen?
Response From P. Dutkowski (Zurich, Switzerland):
Thank you very much, Prof Adam, for your kind comments.
Let me begin with your last question. We included experiments with
deoxygenated perfusion, showing that the effect on the immune re-
sponse was dependent on oxygen in the perfusate, consistent with
earlier studies on reperfusion injury.
Indeed, as we minimized liver ischemia in this model of
the allogeneic rat liver transplantation, we would expect a higher
reperfusion injury and also a higher immune response in grafts
exposed to additional ischemia. Whether HOPE is also effective,
for example, in allogeneic donated after cardiac death livers or
in allogeneic liver grafts with long cold ischemia requires further
investigation.
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